News - OBI Pharma 台灣浩鼎

2016.May.13

未分類

Corporate

Company Position Statement Regarding Recent Investigation of Senior Executives

2016.Mar.31

未分類

Corporate

OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting

2016.Feb.21

未分類

Corporate

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

2015.Oct.05

未分類

Corporate

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

2015.Aug.31

未分類

Corporate

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

2015.Jun.04

未分類

Corporate

Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

2014.Dec.08

未分類

Corporate

Cancer Active Immunotherapy OBI-822 Mechanism Action

2014.Dec.08

未分類

Corporate

Introduction of OBI PHARMA, INC.’s

2014.Jul.21

未分類

Corporate

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

2014.Jan.15

未分類

Corporate

Award & Certification

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

Announcements

Latest announcements

Events

Latest events